Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. It also provides Mondoxyne, a doxycycline-based prescription oral tetracycline antibiotic used as a treatment for acne vulgaris; Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; and Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNOA
Previous Symbol
CUSIPN/A
Phone707-283-0550
Debt
Debt-to-Equity Ratio0.01
Current Ratio3.80
Quick Ratio2.84
Price-To-Earnings
Trailing P/E Ratio-0.24
Forward P/E Ratio-0.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.66 million
Price / Sales0.30
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.48 per share
Price / Book0.31
Profitability
EPS (Most Recent Fiscal Year)($3.16)
Net Income$-14,320,000.00
Net Margins-79.91%
Return on Equity-107.44%
Return on Assets-83.06%
Miscellaneous
Employees79
Outstanding Shares6,590,000
Market Cap$4.91 million
OptionableNot Optionable
Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions
What is Sonoma Pharmaceuticals' stock symbol?
Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."
How were Sonoma Pharmaceuticals' earnings last quarter?
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) released its quarterly earnings results on Thursday, November, 8th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. The company had revenue of $4.94 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 79.91% and a negative return on equity of 107.44%. View Sonoma Pharmaceuticals' Earnings History.
When is Sonoma Pharmaceuticals' next earnings date?
What price target have analysts set for SNOA?
2 Wall Street analysts have issued 1-year target prices for Sonoma Pharmaceuticals' shares. Their predictions range from $3.00 to $7.00. On average, they anticipate Sonoma Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 549.4% from the stock's current price. View Analyst Price Targets for Sonoma Pharmaceuticals.
What is the consensus analysts' recommendation for Sonoma Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sonoma Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sonoma Pharmaceuticals.
What are Wall Street analysts saying about Sonoma Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sonoma Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Sonoma reported F2Q19 (March in total revenues up 13% sequentially, and a net loss of ($2.8M). US product revenues were $2.4M, an increase of 23% from F1Q19. Ex-US revenues also increased to $2.2M, from $2.1M (4% sequential growth) in F1Q19. The company ended the period with $4M in cash, or just over a quarter of operating capital. Conclusion: Sonoma reported modest growth in the quarter and we note that product sales are at record levels, a positive for the company. We are watching for the launch of products in Brazil through partner U.SK (Private), and uptake in the mail order program. Our concern has been the capital needs of the company which Sonoma is currently working to address. We remain Hold rated." (11/9/2018)
- 2. According to Zacks Investment Research, "Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. " (8/29/2018)
Has Sonoma Pharmaceuticals been receiving favorable news coverage?
News articles about SNOA stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sonoma Pharmaceuticals earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Are investors shorting Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals saw a decline in short interest in the month of November. As of November 30th, there was short interest totalling 127,027 shares, a decline of 75.1% from the November 15th total of 509,792 shares. Based on an average daily volume of 320,873 shares, the short-interest ratio is presently 0.4 days. Approximately 2.2% of the company's stock are short sold. View Sonoma Pharmaceuticals' Current Options Chain.
Who are some of Sonoma Pharmaceuticals' key competitors?
Some companies that are related to Sonoma Pharmaceuticals include Citius Pharmaceuticals (CTXR), Pain Therapeutics (PTIE), Genprex (GNPX), THERAPIX BIOSCI/S (TRPX), Fibrocell Science (FCSC), Eyegate Pharmaceuticals (EYEG), Kaya (KAYS), Pulmatrix (PULM), KITOV PHARMA LT/S (KTOV), Sunesis Pharmaceuticals (SNSS), SUMMIT THERAPEU/S (SMMT), NeuroVive Pharmaceutical (NEVPF), Soligenix (SNGX), Edge Therapeutics (EDGE) and Gemphire Therapeutics (GEMP).
Who are Sonoma Pharmaceuticals' key executives?
Sonoma Pharmaceuticals' management team includes the folowing people:
- Mr. James Schutz, CEO, Pres & Director (Age 55)
- Mr. Robert E. Miller, CFO & Corp. Sec. (Age 76)
- Mr. Marc Umscheid, Chief Operating Officer (Age 49)
- Dr. Robert Northey, Exec. VP of R&D (Age 61)
- Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 54)
How do I buy shares of Sonoma Pharmaceuticals?
Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sonoma Pharmaceuticals' stock price today?
One share of SNOA stock can currently be purchased for approximately $0.77.
How big of a company is Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals has a market capitalization of $4.91 million and generates $16.66 million in revenue each year. The company earns $-14,320,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. Sonoma Pharmaceuticals employs 79 workers across the globe.
What is Sonoma Pharmaceuticals' official website?
How can I contact Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected]
MarketBeat Community Rating for Sonoma Pharmaceuticals (NASDAQ SNOA)
MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
